High-performance liquid chromatographic assay for the determination of the novel etoposide derivative dimethylaminoetoposide (NK611) and its metabolites in urine of cancer patients

J Chromatogr B Biomed Appl. 1995 Feb 17;664(2):409-14. doi: 10.1016/0378-4347(94)00481-j.

Abstract

A simple, reproducible and specific urine assay for the novel epipodophyllotoxin derivative dimethylaminoetoposide (NK611, I) its picro form (III), the N-demethyl metabolite (II) and its picro form (IV) is reported. The method involves the addition of Pr-NK611 as internal standard, chloroform extraction and HPLC separation on a Nova-Pak C18 column with a mobile phase of acetonitrile-0.05 M KH2PO4 (pH 6.4) (23:77, v/v). UV detection was used with absorbance monitored at 205 nm and the limit of quantification was 100 ng/ml. The intra- and inter-day precisions were within the ranges 1.1-3.4% and 1.9-2.4% for all analytes and the accuracy was 101-107%. The extraction recovery was more than 88% for I, II and IV and more than 83% for III. The assay is applicable to the urinary monitoring of I-IV in clinical pharmacokinetic investigations.

Publication types

  • Clinical Trial

MeSH terms

  • Administration, Oral
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Agents / urine*
  • Chromatography, High Pressure Liquid
  • Humans
  • Injections, Intravenous
  • Neoplasms / drug therapy
  • Neoplasms / urine*
  • Podophyllotoxin / administration & dosage
  • Podophyllotoxin / analogs & derivatives*
  • Podophyllotoxin / therapeutic use
  • Podophyllotoxin / urine
  • Quality Control
  • Spectrophotometry, Ultraviolet

Substances

  • Antineoplastic Agents
  • NK 611
  • Podophyllotoxin